← Back to Search

Gas

Hyperpolarized Xe129 MRI for COVID-19

Phase 1
Waitlist Available
Research Sponsored by University of Kansas Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6-months
Awards & highlights
No Placebo-Only Group

Summary

This trial will help researchers understand how different levels of COVID-19 severity affect pulmonary function and how quickly patients recover.

Who is the study for?
This trial is for people who had COVID-19 and are in outpatient follow-up. They must be at least 10 days past the start of symptoms, without a fever, able to understand English or Spanish, and have an oxygen saturation of ≥88%. Pregnant individuals, those unable to fit into the MRI vest or hold their breath for about 15 seconds, under 18 years old, or with certain cognitive deficits cannot participate.
What is being tested?
The study is testing hyperpolarized Xe129 MRI's ability to assess lung function in patients who've recovered from mild to severe COVID-19. It aims to provide insights on how well their lungs are working post-infection using this advanced imaging technique.
What are the potential side effects?
There may not be direct side effects from the hyperpolarized Xe129 itself; however, undergoing an MRI might cause discomfort due to having to remain still for a period of time and noise during the procedure. There's also a small risk associated with inhaling xenon gas used in this type of imaging.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6-months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6-months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Ventilation Defect Percentage

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: COVID-19 SurvivorsExperimental Treatment1 Intervention
Subjects recovering from COVID-19 disease will be imaged using hyperpolarized 129Xe MRI.

Find a Location

Who is running the clinical trial?

University of Kansas Medical CenterLead Sponsor
517 Previous Clinical Trials
177,278 Total Patients Enrolled
~0 spots leftby Jan 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top